Quarta-Rad, Inc. reported first-quarter 2026 results with revenue of $25.86K, down from $32.89K a year earlier, and a net loss of $104.18K compared with a net loss of $77.41K in Q1 2025, as the company continued its shift toward software and reseller channels.
Financial Highlights
- Revenue: $25.86K for Q1 2026, compared with $32.89K in Q1 2025; YoY change (21.4%).
- Net income: Net loss $104.18K for Q1 2026, compared with net loss $77.41K in Q1 2025 (loss widened YoY).
Business Highlights
- Revenue trend: Net revenue declined about 21% YoY to $25.9K in Q1 2026, driven by reduced legacy Quarta‑Rad sales and the timing of Sellavir revenue recognition.
- Channel shift: Management is phasing out legacy radiation-product sales and moving primary go‑to‑market efforts to the Sellavir software business and Japanese reseller channels.
- Product focus & momentum: The company is pivoting strategically to the CenterEye AI call‑center platform with an intended subscription model and ongoing development activity.
- Operational spend & scale: Increased operating expenses for Sellavir and higher stock‑based compensation contributed to larger operating losses despite lower cost of goods sold.
- Near-term plan: Management is prioritizing software development, marketing spend (targeting $25K–$75K), and building reseller partnerships to drive pilot deployments.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.